News / Taiwan / economic_daily
Genovate August Revenue Surges 50% as Hormone Plant Clears Japanese Regulatory Hurdle
Health Technology · Pharmaceuticals: Major · economic_daily · 2026-09-08
4114
Genovate's August revenue grew 50% year-over-year, bolstered by strong sales in oncology and women's health, alongside a key regulatory approval from Japan's PMDA.
What Happened
Revenue Growth: Genovate reported a 50% year-over-year increase in August revenue to NT$750 million, bringing the cumulative eight-month total to NT$5.096 billion, a 26% growth. Strong performance across oncology, cardiovascular, and women's health product lines has significantly bolstered the company's financial results.
Product Momentum: The company's nasal sprays and six-month long-acting hormone therapies have shown exceptional growth, with the latter leading the market in prostate cancer and pediatric precocious puberty treatments. Recently launched drugs for digestive and women's health are also gaining rapid traction across major medical institutions.
International Expansion: Genovate has successfully secured distribution partnerships in Vietnam and achieved a major milestone with its hormone plant passing the Japanese PMDA inspection. These developments pave the way for entry into the Japanese market and broader international collaborations in the coming years.
Market Strategy: By leveraging professional medical education and academic exchanges, Genovate continues to solidify its influence in urology and cardiovascular health. The company remains focused on introducing innovative therapies and enhancing manufacturing efficiency to evolve into a leading regional pharmaceutical group.